FDA Grants PharmassêtX Orphan Drug Designation for Treatment of Rare Form of Inflammatory Bowel Disease with Active Component from Green Tea

Clinical trials slated to begin next year in collaboration with global leader LOUISVILLE, Ky., July 10, 2024 /PRNewswire/ — PharmassêtX Inc., a late-preclinical stage pharmaceutical development company, today announced that the US Food and Drug Administration (FDA) has granted Orphan…